Configuration and preferential solid-state conformations of perindoprilat (S-9780). Comparison with the crystal structures of other ACE inhibitors and conclusions related to structure-activity relationships.
about
Sustained release of prindopril erbumine from its chitosan-coated magnetic nanoparticles for biomedical applications.Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme.Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite.The Development and Validation of a Stability-Indicating UHPLC-DAD Method for Determination of Perindopril l-Arginine in Bulk Substance and Pharmaceutical Dosage Form.Perindoprilat monohydrate.Novel pseudopolymorph of the active metabolite of perindopril.
P2860
Configuration and preferential solid-state conformations of perindoprilat (S-9780). Comparison with the crystal structures of other ACE inhibitors and conclusions related to structure-activity relationships.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Configuration and preferential ...... ucture-activity relationships.
@en
Configuration and preferential solid-state conformations of perindoprilat
@nl
type
label
Configuration and preferential ...... ucture-activity relationships.
@en
Configuration and preferential solid-state conformations of perindoprilat
@nl
prefLabel
Configuration and preferential ...... ucture-activity relationships.
@en
Configuration and preferential solid-state conformations of perindoprilat
@nl
P2093
P356
P1476
Configuration and preferential ...... ucture-activity relationships.
@en
P2093
P304
P356
10.1021/JM00106A030
P407
P577
1991-02-01T00:00:00Z